Ignite Creation Date:
2025-12-25 @ 12:09 AM
Ignite Modification Date:
2026-06-05 @ 7:54 PM
Study NCT ID:
NCT01278758
Status:
TERMINATED
Last Update Posted:
2020-12-09
First Post:
2011-01-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Dose-escalation Pharmacokinetic Study of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and Patients With Normal Renal Function
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Advanced or metastatic cancer, | View |
| None | refractory, | View |
| None | core phase, | View |
| None | extension phase, | View |
| None | dose escalation, | View |
| None | standard chemotherapy, | View |
| None | doctaxel, | View |
| None | paclitaxel, | View |
| None | carboplatin, | View |
| None | safety, | View |
| None | tolerability | View |